NCT05999994

A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer

CAMPFIRE: Children's and Young Adult Master Protocol for Innovative Pediatric Research

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 105 (estimated)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 1 Year – 39 Years
• Healthy volunteers: Not accepted

Summary

The main purpose of the master is to help the research sites and sponsor carry out several clinical trials more efficiently by providing a common research protocol. Individual clinical trials under this master protocol define drug/disease-specific research goals and activities to test them. New studies will be added as new drugs emerge against different cancers. Participation in the trial will depend on how long the benefit lasts.

Conditions

• Neoplasms
• Child
• Adolescent

Interventions

Type	Name	Description
DRUG	Ramucirumab	Administered IV
DRUG	Cyclophosphamide	Administered orally
DRUG	Vinorelbine	Administered IV
DRUG	Gemcitabine	Administered IV
DRUG	Docetaxel	Administered IV
DRUG	Abemaciclib	Administered orally
DRUG	Irinotecan	Administered IV
DRUG	Temozolomide	Administered orally

Timeline

• Start date: 2020-01-22
• Primary completion: 2027-05-01
• Completion: 2027-05-01
• First posted: 2023-08-21
• Last updated: 2026-03-27

Locations

73 sites across 10 countries: United States, Australia, Belgium, France, Germany, Italy, Japan, Netherlands, Spain, United Kingdom

Regulatory

• FDA-regulated drug study